- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Q4/24 results/pipeline expansion - Buy | 131 | dpa-AFX | Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH 03.04.2025 / 17:08 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer... ► Artikel lesen | |
| Do | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Do | Pharming Group N.V. - 20-F, Annual and transition report of foreign private issuers | 4 | SEC Filings | ||
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| Do | Pharming Group N.V.: Pharming Group announces the filing of its 2024 Annual Report and Form 20-F | 3 | GlobeNewswire (USA) | ||
| 28.03. | Pharming Group N.V.: Pharming Group to participate in April investor conferences | 182 | GlobeNewswire (Europe) | Leiden, the Netherlands, March 28, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences... ► Artikel lesen | |
| 20.03. | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 20.03. | Pharming Group N.V.: Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation | 303 | GlobeNewswire (Europe) | Multi-center clinical trial includes sites located in the US, UK and EU
Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs)
CVID patients demonstrate... ► Artikel lesen | |
| 18.03. | NICE recommends Pharming's Joenja as first treatment for ultra-rare immune disease APDS | 4 | PMLiVE | ||
| 16.03. | Pharming Group NV zeigt Umsatzwachstum und stabilisiert Verluste | 10 | IT BOLTWISE | ||
| 14.03. | What Analysts Are Saying About Pharming Stock | 10 | Benzinga.com | ||
| 14.03. | Pharming Group outlines 2025 revenue guidance of $315M to $335M driven by RUCONEST and Joenja growth | 2 | Seeking Alpha | ||
| 13.03. | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.03. | Pharming reports Q4 results | 3 | Seeking Alpha | ||
| 13.03. | Pharming Group Swings To Q4 Profit | 5 | RTTNews | ||
| 13.03. | Pharming Group N.V.: Pharming Group reports fourth quarter and full year 2024 financial results and provides business update | 393 | GlobeNewswire (Europe) | Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total revenues... ► Artikel lesen | |
| 06.03. | PHARMING TECHNOLOGIES B V: Pharming Technologies B.V. announces the final outcome of the recommended cash offer to the shareholders of Abliva AB (publ) | 11 | Cision News | ||
| 04.03. | Pharming Group N.V.: Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders | 351 | GlobeNewswire (Europe) | Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders... ► Artikel lesen | |
| 04.03. | Pharming Group N.V. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 27.02. | Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2024 financial results on March 13 | 229 | GlobeNewswire (Europe) | Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year... ► Artikel lesen | |
| 25.02. | PHARMING TECHNOLOGIES B V: Pharming Technologies B.V. announces a supplement to the offer document in respect of the recommended cash offer to the shareholders of Abliva AB (publ) | 4 | Cision News |
Seite:
1 2 3 4 Weiter >>
70 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 5,966 | -1,45 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,114 | +0,32 % | PacBio Grants Equity Incentive Award to New Employee | ||
| CENTOGENE | 0,120 | 0,00 % | Centogene NV: CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 12, 2025 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company") today announced it has closed its transaction to sell... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,129 | -5,41 % | Berenberg starts atai Life Sciences coverage with Positive rating | ||
| BIOMERIEUX | 114,00 | +0,53 % | bioMérieux receives FDA 510(k) Clearance for its VITEK COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance | MARCY L'ÉTOILE, France, March 18, 2025 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration... ► Artikel lesen | |
| CYCLACEL | 0,296 | -100,00 % | Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update | BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,850 | -22,02 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| GENUS | 21,600 | +0,93 % | Dividendenbekanntmachungen (04.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERICAN EXPRESS COMPANY US0258161092 0,82 USD 0,742 EUR BARCLAYS PLC GB0031348658 0,055 GBP EUR BRISTOL-MYERS SQUIBB COMPANY US1101221083 0... ► Artikel lesen | |
| ANAPTYSBIO | 17,100 | +1,18 % | AnaptysBio, Inc.: Anaptys Announces Stock Repurchase Plan | SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that... ► Artikel lesen | |
| ABIONYX PHARMA | 1,160 | -1,53 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| MEIRAGTX | 5,900 | +13,46 % | MeiraGTx Holdings plc - 8-K, Current Report | ||
| METABOLIC EXPLORER | 0,095 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 09.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 09.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 09.10.2024ISIN NameAU0000064966 VIRG.MON.... ► Artikel lesen | |
| AKESO | 9,900 | +1,02 % | Akeso, Inc.: Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies | Key Highlights:
Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline... ► Artikel lesen | |
| MAAT PHARMA | 5,800 | -5,54 % | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen |
Das Unternehmen PHARMING GROUP NV ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,950 Euro und damit -0,71 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.
